Relay Therapeutics (NASDAQ:RLAY) Price Target Raised to $19.00

Relay Therapeutics (NASDAQ:RLAY) had its target price hoisted by HC Wainwright from $14.00 to $19.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Relay Therapeutics’ Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.49) EPS.

A number of other equities analysts have also recently issued reports on the stock. Guggenheim raised their target price on shares of Relay Therapeutics from $15.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Oppenheimer reaffirmed an “outperform” rating on shares of Relay Therapeutics in a report on Monday, March 16th. Citizens Jmp increased their price target on Relay Therapeutics from $15.00 to $17.00 and gave the stock a “market outperform” rating in a research report on Tuesday, March 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Finally, Wells Fargo & Company boosted their price objective on Relay Therapeutics from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Relay Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Relay Therapeutics Stock Performance

Shares of NASDAQ:RLAY opened at $9.60 on Monday. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -5.93 and a beta of 1.55. Relay Therapeutics has a 1-year low of $1.77 and a 1-year high of $11.49. The company’s fifty day moving average is $9.02 and its two-hundred day moving average is $7.55.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.06. The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $4.34 million. Sell-side analysts expect that Relay Therapeutics will post -2.55 EPS for the current fiscal year.

Insider Activity

In other Relay Therapeutics news, insider Donald A. Bergstrom sold 18,895 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $143,979.90. Following the sale, the insider owned 422,733 shares in the company, valued at approximately $3,221,225.46. This trade represents a 4.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter Rahmer sold 11,684 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $89,032.08. Following the sale, the insider directly owned 277,964 shares in the company, valued at approximately $2,118,085.68. This trade represents a 4.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 93,302 shares of company stock valued at $724,355. Company insiders own 4.87% of the company’s stock.

Institutional Trading of Relay Therapeutics

Several large investors have recently added to or reduced their stakes in RLAY. Franklin Resources Inc. boosted its holdings in shares of Relay Therapeutics by 130.4% in the second quarter. Franklin Resources Inc. now owns 394,122 shares of the company’s stock valued at $1,364,000 after acquiring an additional 223,042 shares in the last quarter. Congress Asset Management Co. increased its stake in shares of Relay Therapeutics by 160.9% during the third quarter. Congress Asset Management Co. now owns 408,842 shares of the company’s stock valued at $2,134,000 after acquiring an additional 252,142 shares during the period. Geode Capital Management LLC raised its holdings in Relay Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock worth $11,176,000 after purchasing an additional 159,548 shares in the last quarter. Commodore Capital LP lifted its position in Relay Therapeutics by 27.3% in the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after purchasing an additional 3,650,000 shares during the period. Finally, Bellevue Group AG lifted its position in Relay Therapeutics by 11.6% in the second quarter. Bellevue Group AG now owns 8,230,870 shares of the company’s stock worth $28,479,000 after purchasing an additional 853,578 shares during the period. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised 2026 EPS forecasts across quarters and for the full year, cutting projected losses (Q1: from ($0.43) to ($0.36); Q2: ($0.44)→($0.37); Q3: ($0.45)→($0.38); Q4: ($0.46)→($0.38); FY2026: ($1.78)→($1.49)). The firm keeps a “Buy” rating with a $19 price target — a clear positive analyst catalyst that can support further upside. HC Wainwright Forecasts Strong Price Appreciation for Relay Therapeutics (NASDAQ:RLAY) Stock
• Neutral Sentiment: Short-interest reports for March show zero shares short and nonsensical NaN changes across filings — likely a data/reporting anomaly. This item is not a reliable driver of price action unless updated with corrected figures.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.